Staphylococcal Acute Post-Operative PJI Treated With 'DAIR' And Impact Of Rifampin (IPASTAPH)

Civil Hospices of Lyon

Status: Completed

Conditions: Bone and Joint Infection; Antibiotic Resistant Staphylococcus Aureus Infection

Treatments: Other: Role of rifampin in staphylococcal PJI

Study type: Observational

Funder types: Other

Identifiers

NCT03750721

18-040

Details and patient eligibility

About

S. aureus and coagulase-negative staphylococci are the most frequent bacteria responsible for PJI (prosthetic joint infection). The aim of this study is to describe the use of rifampicin.

Enrollment: 79 patients

Sex: All

Ages: 18 to 100 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

patients having had acute PJI (i.e. <1 month following the implantation), DAIR with exchange of removal components) due to S. aureus and coagulase-negative staphylococci (2011-2016)

Exclusion criteria

None

Trial design

79 participants in 1 patient group

Role of rifampin in staphylococcal PJI

Description:

retrospective cohort study in 4 hospitals : patients with staphylococcal acute post-operative (\< 1 month) PJI treated with DAIR in 2011-2016 period

Treatment:

Other: Role of rifampin in staphylococcal PJI